Loading company…
Vivet Therapeutics SAS develops gene therapies for orphan diseases, including VTX-806 for cerebrotendinous xanthomatosis.
Vivet Therapeutics SAS develops gene therapies and orphan drugs for rare inherited metabolic disorders. Its AAV-based product VTX-806 targets cerebrotendinous xanthomatosis (CTX). Founded in 2016 and based in Paris, France, by CEO Jean-Philippe Combal and CSO Gloria Gonzalez-Aseguinolaza, the company raised EUR 4.9 million in grant funding from France 2030 in February 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in